Evidence map›Paper›PMID 26194455›Full record

ArticleEuropean radiology2016

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

E Neri, M A Bali, A Ba-Ssalamah, P Boraschi, G Brancatelli, F Caseiro Alves, L Grazioli, T Helmberger, J M Lee, R Manfredi and 9 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Radiological assessment of secondary biliary tree lesions: an update.The Journal of international medical research · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Motion Mitigation Techniques for Abdominal and Cardiac MR Imaging.Journal of magnetic resonance imaging : JMRI · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Liver metastases: The role of magnetic resonance imaging.World journal of gastroenterology · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

E NeriDepartment of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy. emanuele.neri@med.unipi.it.
M A BaliDepartment of Radiology, Hôpital Erasme, MRI Clinics, Bruxelles, Belgium.
A Ba-SsalamahDepartment of Biomedical Imaging and Image-guided Therapy, The General Hospital of the Medical University of Vienna, Vienna, Austria.
P BoraschiDepartment of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy.
G BrancatelliDepartment of Radiology, University of Palermo, Palermo, Italy.
F Caseiro AlvesMedical Imaging Department and Faculty of Medicine, University Hospital of Coimbra, Coimbra, Portugal.
L GrazioliDepartment of Radiology, Spedali Civili di Brescia, Brescia, Italy.
T HelmbergerDepartment of Diagnostic and Interventional Radiology and Nuclear Medicine, Klinikum Bogenhausen, Academic Teaching Hospital of the Technical University, Munich, Germany.
J M LeeDivision of Abdominal Imaging, Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
R ManfrediDepartment of Radiology, University of Verona, Verona, Italy.
L Martì-BonmatìÁrea Clínica de Imagen Médica, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
C MatosDepartment of Radiology, Hôpital Erasme, MRI Clinics, Bruxelles, Belgium.
E M MerkleKlinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel, Switzerland.
B Op De BeeckDepartment of Radiology, Antwerp University Hospital, Edegem, Belgium.
W SchimaDepartment of Diagnostic and Interventional Radiology, KH Goettlicher Heiland, Krankenhaus der Barmherzigen Schwestern and Sankt Josef-Krankenhaus, Vienna, Austria.
S SkehanDepartment of Radiology, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
V VilgrainRadiology Department, Assistance Publique-Hôpitaux de Paris, APHP, Hôpital Beaujon, Clichy, Paris, France.
C ZechAbteilungsleiter Interventionelle Radiologie, Klinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel, Switzerland.
C BartolozziDepartment of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents.

methodsThe European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach's statistics were used to rate levels of agreement and internal reliability of the consensus.

resultsThree Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases.

conclusionsThe consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. KEY POINTS: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.

Indexed as

Contrast MediaAdenoma, Liver CellBile DuctsConsensusDelphi TechniqueDiagnosis, DifferentialHumansLiver DiseasesLiver NeoplasmsMagnetic Resonance ImagingRadiography, AbdominalReproducibility of ResultsContrast MediaBiliary tractContrast mediaDelphi techniqueLiverMagnetic resonance imaging

Identifiers

PMID26194455
PMCPMC4778143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.